Implantica announces new health-economics data publication showing RefluxStop™’s superior cost-effectiveness for the Swiss healthcare system
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, reports the study, “Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease,” was published recently by the Journal of Medical Economics %20is,MSA%5D)%20in%20selected%20cases)1.The comprehensive health economic analysis published in this study found that RefluxStop™ is highly likely to be a cost-effective treatment for GERD